Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Research & Development (2023 - 2025)

Historic Research & Development for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $28.5 million.

  • Inhibrx Biosciences' Research & Development fell 2663.2% to $28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.0 million, marking a year-over-year decrease of 5205.47%. This contributed to the annual value of $203.7 million for FY2024, which is 631.55% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported Research & Development of $28.5 million as of Q3 2025, which was down 2663.2% from $22.3 million recorded in Q2 2025.
  • Inhibrx Biosciences' Research & Development's 5-year high stood at $82.1 million during Q4 2023, with a 5-year trough of $22.3 million in Q2 2025.
  • Its 3-year average for Research & Development is $44.6 million, with a median of $37.5 million in 2023.
  • As far as peak fluctuations go, Inhibrx Biosciences' Research & Development soared by 9829.94% in 2024, and later plummeted by 6707.62% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Research & Development (Quarter) stood at $82.1 million in 2023, then tumbled by 59.35% to $33.4 million in 2024, then dropped by 14.48% to $28.5 million in 2025.
  • Its last three reported values are $28.5 million in Q3 2025, $22.3 million for Q2 2025, and $36.9 million during Q1 2025.